Log in to search using one of your social media accounts:


GSE31335 Characterization of the small RNAome in acute myeloid leukemia and discovery of novel small RNA species by deep sequencing (Illumina)

Contributors : Jun Wang ; Jacek Marzec ; Floriana Manodoro ; Charles Mein ; Alessandra Curtotti ; Bryan D Young ; Silvana DebernardiSeries Type : Non-coding RNA profiling by high throughput sequencingOrganism : Homo sapiensWe used small RNA seq (Illumina) to characterise and quantify the miRNA and small non-coding (snc)RNA transcriptome of 38 libraries of size-fractionated RNA obtained from AML patients and normal bone marrow. We detected the expression of 765 known miRNAs and 2554 uniquely located species of sncRNAs. A total of 575 potential miRNA candidate hairpins were identified. We also identified 37 C/D Box and 51 H/ACA Box, potential novel snoRNAs.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Non-coding RNA profiling by high throughput sequencing Homo sapiens Source Type: research

Related Links:

Condition:   Acute Myeloid Leukemia Intervention:   Drug: Minnelide Sponsors:   Justin Watts;   Minneamrita Therapeutics LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSION:Our data showed a high frequency of NPM1 mutations in the monocytic subtypes of AML, as well as a high degree of association between the occurrence of NPM1 and FLT3/ITD mutations. Ann Saudi Med 2011 ; 31(1): 45-50PMID: 21245599 DOI: 10.4103/0256-4947.75778
Source: Annals of Saudi Medicine - Category: General Medicine Tags: ISSUE 1 Source Type: research
Publication date: Available online 15 November 2017 Source:The Lancet Haematology Author(s): Berend Snijder, Gregory I Vladimer, Nikolaus Krall, Katsuhiro Miura, Ann-Sofie Schmolke, Christoph Kornauth, Oscar Lopez de la Fuente, Hye-Soo Choi, Emiel van der Kouwe, Sinan Gültekin, Lukas Kazianka, Johannes W Bigenzahn, Gregor Hoermann, Nicole Prutsch, Olaf Merkel, Anna Ringler, Monika Sabler, Georg Jeryczynski, Marius E Mayerhoefer, Ingrid Simonitsch-Klupp, Katharina Ocko, Franz Felberbauer, Leonhard Müllauer, Gerald W Prager, Belgin Korkmaz, Lukas Kenner, Wolfgang R Sperr, Robert Kralovics, Heinz Gisslinger, Peter ...
Source: The Lancet Haematology - Category: Hematology Source Type: research
Publication date: November 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 11 Author(s): Kendra Sweet, Jeffrey Lancet As our general understanding regarding the complex nature of acute myeloid leukemia (AML) is expanding, so is our ability to translate this biological data into clinically relevant information. The use of whole genome and whole exome sequencing has begun to shed light on the importance of a variety of somatic mutations that are frequently identified in AML. In turn, this has allowed the field to incorporate mutational data into prognostic classifications which can guide treatment decis...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion Our data seem to confirm the value of FLAG-Ida in this setting and might suggest its best usage as bridge therapy for patients awaiting allotransplantation. Micro-Abstract Allotransplant is crucial for improving survival in refractory/first relapsed AML patients. An overall response was achieved in 48 patients (44% of the whole group) with FLAG-Ida chemotherapy approach. 24 of 48 responders underwent allotransplantation obtaining a median OS of 60 months.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
The objectives of this article are to equip oncology nurse to identify patients with hyperleukocytosis and to provide nursing interventions that will ensure safe, quality care. METHODS: A case study is used to demonstrate key concepts that are critical in early assessment, identification, and treatment of patients with leukostasis.
. FINDINGS: Oncology nurses well versed in the pathophysiology, clinical presentation, and management of leukostasis can make a significant contribution to the safe management of patients with cancer. PMID: 29149122 [PubMed - in process]
Source: Clinical Journal of Oncology Nursing - Category: Nursing Authors: Tags: Clin J Oncol Nurs Source Type: research
This article is protected by copyright. All rights reserved
Source: Journal of Cellular Physiology - Category: Cytology Authors: Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Publication date: 16 November 2017 Source:Cell, Volume 171, Issue 5 Author(s): John E.J. Rasko, Timothy P. Hughes Activating mutations of FLT3 occur in about 30% of acute myeloid leukemia (AML) cases and are associated with relapse and poor prognosis. Midostaurin is the first drug approved for AML since 2000, and the first multi-kinase inhibitor approved for the FLT3-mutant subtype. To view this Bench to Bedside, open or download the PDF. Teaser Activating mutations of FLT3 occur in about 30% of acute myeloid leukemia (AML) cases and are associated with relapse and poor prognosis. Midostaurin is the first drug approved fo...
Source: Cell - Category: Cytology Source Type: research
Authors: Ertz-Archambault N, Kelemen K Abstract Based on the current WHO Classification of Myeloid Neoplasms, cytogenetic findings play a central role in the diagnostic classification of the myeloid malignancies. Cytogenetic abnormalities detected at primary diagnosis may change over time. Karyotype changes can be characterized as cytogenetic evolution, cytogenetic regression or a combination of both. While the exact mechanism of cytogenetic evolution is not completely understood, the process of cytogenetic evolution is not random, but follows different, and often disease-specific patterns during progression and re...
Source: Panminerva Medica - Category: General Medicine Tags: Panminerva Med Source Type: research
Abstract Acute myeloid leukemias secondary (sAML) to myeloproliferative neoplasms (MPN) have variable clinical courses and outcomes, but remain almost always fatal. Large cohorts of sAML to MPN are difficult to obtain and there is very little scientific literature or prospective trials for determining robust prognostic markers and efficient treatments. We analyzed event‐free survival (EFS) and overall survival (OS) of 73 patients with MPN who progressed to sAML, based on their epidemiological characteristics, the preexisting MPN, the different treatments received, the different prognostic groups and the responses achieve...
Source: American Journal of Hematology - Category: Hematology Authors: Tags: Research Article Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Databases & Libraries | Genetics | Leukemia